The authors determined the impact of postmastectomy radiotherapy (PMRT) on overall survival (OS) among patients with pT3N0M0 breast cancer in the National Cancer Data Base. METHODS: A total of 3437 patients with pT3N0M0 breast cancer who initially were treated with mastectomy between 2003 and 2011 were identified. Of these women, 1644 (47.8%) received PMRT (67% treated with chest wall RT alone and 33% treated with chest wall and regional lymph node irradiation). Univariable and multivariable analyses were conducted to identify characteristics associated with PMRT and OS. In addition, propensity score matching and interaction effect testing also were performed. RESULTS: PMRT was associated with age <40 years, private insurance coverage, treatment facility location within 10 miles of the patient's home zip code, Charlson-Deyo comorbidity score of 0, tumor size 7 cm, and treatment with chemotherapy or hormone therapy (all P<.05). PMRT was associated with improved 5-year OS (86.3% for patients treated with PMRT vs 66.4% for patients not treated with PMRT; P<.01). In addition to PMRT (hazard ratio, 0.72; 95% confidence interval, 0.59-0.87 [P<.01]), age 50 years, treatment at an academic/research program, Charlson-Deyo comorbidity score of 0, tumor size <7 cm, chemotherapy receipt, and hormone therapy receipt were associated with improved OS on multivariable analyses (all P<.05). Interaction testing found that PMRT improved OS independent of age, facility type, Charlson-Deyo comorbidity score, tumor grade and size, surgical margin status, and receipt of chemotherapy or hormone therapy (all P>
INTRODUCTION
In 2016, a total of 246,660 new cases of breast cancer are expected to be diagnosed, with >40,000 women dying of this disease. 1 Although the overall incidence of breast cancer is high, the number of large primary breast malignancies without lymph node involvement is small because the risk of lymph node disease generally increases with tumor size. [2] [3] [4] In fact, the majority of series published to date have estimated that only 1% to 4% of all breast cancers are >5 cm and lymph node negative (pT3N0). [5] [6] [7] [8] [9] [10] [11] Therefore, very few patients with T3N0 disease have received treatment as part of a randomized trial examining postmastectomy radiotherapy (PMRT). Thus, the question of whether PMRT is warranted in this subgroup of patients remains controversial because previous retrospective studies have found differing results, and randomized trials demonstrating the overall survival (OS) benefit of PMRT included only a small number of patients with pT3N0 breast cancer. [5] [6] [7] 9, 10, [12] [13] [14] Current National Comprehensive Cancer Network guidelines state that RT to the chest wall, with or without regional lymph node irradiation (RNI), should be considered for patients with pT3N0 breast cancer. 11 The American College of Radiology Appropriateness Criteria for postmastectomy RT states that "given the conflicting prospective and retrospective data, treatment of pT3N0 patients should continue to be highly individualized." 15 Given the lack of clarity regarding the use of PMRT in patients with pT3N0 breast cancer and the infrequency with which these women are treated at any single institution, we used the National Cancer Data Base (NCDB) to identify a large cohort of patients with pT3N0 breast cancer and to identify factors associated with the receipt of PMRT. Our primary goal was to determine the impact of PMRT on OS. Given recent studies demonstrating the disease-free survival benefit of RNI, 16, 17 we also evaluated the role of RNI within this clinical context.
MATERIALS AND METHODS

NCDB Criteria
The NCDB is a large, prospectively acquired database, drawn from cases from the American College of Surgeons Commission on Cancer-accredited institutions across the United States. This database captures approximately 70% of all newly diagnosed malignancies. The data set includes detailed information regarding patient, disease, and treatment characteristics as well as survival outcomes. The data set includes detailed RT information regarding treatment site and RT source and dose, as well as detailed surgical and pathological information including surgery type, surgical margin status, and number of lymph nodes removed.
The breast NCDB was queried for patients aged >18 years who were diagnosed from 2003 to 2011. To be included in this study, women could not have had a previous cancer diagnosis and had to have pT3N0M0 breast cancer that was treated with initial total mastectomy, modified radical mastectomy, or radical mastectomy. Women were excluded if they were treated with cobalt-60, brachytherapy, or other non-megavoltage photon beam RT. Women without RT records or survival information also were excluded (Fig. 1) . The following patient characteristics were examined: age (<40 years, 40-50 years, and >50 years); race (white, black, or other); insurance coverage (not insured, private insurance, or government insurance); patient's county of residence (urban, rural, or metropolitan as defined by the US Census Bureau); distance from patient's residence zip code to treatment facility (<10 miles, 10-50 miles, or >50 miles); year of diagnosis; percentage of residents without a high school degree within the patient's home county (<7%, 7%-12.9%, 13%-20%, and 21% quartiles); median income of patient's county of residence (<$38,000, $38,000-$47,999, $48,000-$62,999, and $63,000 as determined by the 2012 American Community Survey); and comorbidities as quantified by the Charlson-Deyo comorbidity score (0 [indicating no comorbidities] vs 1). 18, 19 The following disease characteristics were evaluated: tumor laterality (right vs left); tumor size (<7.0 cm vs 7.0 cm); tumor grade; lymphovascular invasion (LVSI); and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. Finally, the following treatment characteristics also were evaluated: treatment facility type (community cancer center, comprehensive community cancer center, or academic/research program); treatment facility location within the United States (Northeast, South, Midwest, and West); type of mastectomy performed (total, modified radical, or radical); surgical margin status (positive vs negative); number of lymph nodes removed (<8, 8-12, or >12 lymph nodes); receipt of PMRT (yes vs no); RT fields (chest wall only or chest wall plus RNI); receipt of chemotherapy (yes vs no); and receipt of hormone therapy (yes vs no).
Statistical Analysis
Statistical analysis was conducted using SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC) and SAS macros developed by the Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute in Atlanta, Georgia. 20 Descriptive statistics for each variable were determined. The univariate association (UVA) of each covariate with the use of PMRT was assessed using the chi-square test for categorical covariates and analysis of variance for numerical covariates. The primary endpoint of OS was defined as the time between surgery and death from any cause or the time of last follow-up. The UVA of each variable above with OS was tested using Cox proportional hazards models and log-rank tests. A multivariable Cox proportional hazard model (MVA) was fit by a backward elimination method applying P 5 .20 removal criteria. LVSI and HER2 status could not be included in the MVA due to the high number of patients for whom this information was missing. The effect of PMRT on OS stratified by different variables was estimated by testing the interaction effect between PMRT and each relevant variable. Separate UVA and MVA were performed stratifying PMRT as either to the chest wall alone or chest wall and RNI. Kaplan-Meier plots were produced to compare the survival curves by subgroups along with the log-rank P value, and P<.05 was considered to be statistically significant.
The propensity score matching (PSM) method then was conducted to address a potential treatment selection bias. A logistic regression model predicting whether PMRT was used was performed to predict the propensity score by age, race, facility type and location, insurance status, county of residence, distance to the treatment facility from the patient's home zip code, year of diagnosis, educational and income level of residents with the patient's home zip code, Charlson-Deyo comorbidity score, laterality, grade, ER and PR status, surgical margin status, number of regional lymph nodes examined, use of Original Article Figure 1 . Consolidated Standards Of Reporting Trials (CONSORT) diagram of the study population. The National Cancer Data Base (NCDB) was queried for breast cancer cases from 2003 to 2011, yielding a total of 1,960,544 cases. A total of 3437 women who were treated with initial mastectomy for pathologic T3N0M0 breast cancer who met the study inclusion and exclusion criteria were identified. Of these women, 1793 were not treated with postmastectomy radiotherapy (PMRT) whereas 1644 women did receive PMRT. *Information regarding radiation field and target was not available for 43 patients treated with PMRT. chemotherapy, use of hormone therapy, and tumor size. HER2 status and LVSI could not be used in the PSM model due to the high number of patients who were missing this information. Patients from each study cohort were matched to each other at ratio of 1:1 based on the propensity score using a greedy 5-1 digit match algorithm. 21 After matching, the balance of covariates between the 2 cohorts was evaluated by the standardized differences and a value of <0.1 was considered as a negligible imbalance. 22 The effects were estimated in the matched sample by a Cox model with a robust variance estimator for OS. 23 
RESULTS
Patient, Tumor, and Treatment Characteristics
A total of 3437 patients met study entry criteria (Fig. 1) , 1644 of whom (47.8%) received PMRT. The median age of the patients was 63 years (range, 20-90 years). The median distance from the patient's home zip code to the treatment facility was 8.1 miles (range, 0-2567 miles). The median tumor size was 6 cm (range, 5.1-9.0 cm). The median number of lymph nodes examined was 3 (range, 1-46 lymph nodes). The NCDB does not adequately capture sentinel lymph node biopsy versus axillary lymph node dissection procedures, but 14.6% of patients had 1 lymph node, 15.7% of patients had 2 lymph nodes, and 13.4% of patients had 3 lymph nodes removed. In total, approximately 67% of patients had <8 lymph nodes excised. The median PMRT dose was 50.4 grays (range, 46-60 grays). Table 1 summarizes the study population characteristics.
Predictors of PMRT
On UVA, factors found to be associated with the use of PMRT were patient age <50 years, white race, a Charlson-Deyo comorbidity score of 0, private insurance coverage, median county residence income of $48,000, relatively high educational status with <13% of county residents without a high school diploma, treatment facility location in the Northeast or West, treatment facility located <50 miles from the patient's home zip code, diagnosis made between 2009 and 2011, moderately differentiated tumors, ER-positive tumors, bilateral mastectomy performed, and use of chemotherapy and/or hormone therapy (all P<.05) ( Table 1) . On MVA, age <40 years (vs age >50 years), a Charlson-Deyo comorbidity score of 0, private insurance coverage (vs government insurance coverage), treatment facility location <10 miles from the patient's home zip code (vs >50 miles from the patient's home zip code), tumor size 7 cm, use of chemotherapy, and use of hormone therapy were associated with receipt of PMRT (all P<.05) ( Table 2 ).
Impact of PMRT on OS
The median follow-up was 55.7 months (95% confidence interval [95% CI], 54.4-57.5 months). The 5-year OS rate was 86.3% in patients treated with PMRT versus 66.4% in patients not treated with PMRT (P<.001) (Fig.  2) Table 3 ). On MVA, additional factors found to be associated with improved OS included age 50 years, treatment at an academic/research program (vs community cancer program), treatment at a facility located in the West (vs Midwest), private insurance (vs government insurance) coverage, a Charlson-Deyo comorbidity score of 0, tumor size <7 cm, and receipt of chemotherapy and hormone therapy (all P<.05) ( Table 3 ). Interaction tests revealed that the influence of PMRT on OS was not dependent on the different levels of other variables associated with OS on MVA. Specifically, there was no significant interaction observed between PMRT and insurance status, age, Charlson-Deyo comorbidity score, tumor size, treatment facility location or type, or receipt of chemotherapy or endocrine therapy (all P>.10), indicating a benefit of PMRT across all strata within these variables.
After matching, PSM analysis identified 711 patients treated with PMRT and not treated with PMRT. The 2 groups of patients were well balanced with regard to patient, tumor, and treatment characteristics (all <0.1) (see Supporting Information Table 2 ). On PSM, the 5-year actuarial OS rate was 83.0% in the patients treated with PMRT compared with 75.8% in the patients not treated with PMRT (P 5 .01) (Fig. 3) . On Cox proportional hazards analysis, PMRT was found to be associated with improved OS (HR, 0.75; 95% CI, 0.58-0.94 [P 5 .016]).
Impact of Chemotherapy
Among patients who did not receive chemotherapy, the actuarial 5-year OS rate was 78.1% in patients receiving PMRT compared with 57.2% in those who did not (P<.001) (Fig. 4A ). In addition, the benefit of PMRT also was noted among patients who received chemotherapy, in whom the actuarial 5-year OS rate was 88.8% in patients treated with PMRT versus 85.6% in patients not treated with PMRT (P<.001) (Fig. 4B ).
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Impact of Hormone Therapy
Among patients who did not receive hormone therapy, the actuarial 5-year OS rate was 77.4% in patients receiving PMRT compared with 59.2% in those who did not (P<.001) (Fig. 4C) . The benefit of PMRT also was noted among patients treated with hormone therapy, in whom the actuarial 5-year OS rate was 90.9% in patients treated with PMRT versus 76.1% in patients not treated with PMRT (P<.001) (Fig. 4D) .
Impact of RNI
Among the 1644 patients who received RT, approximately 33% (550 patients) received RNI in addition to PMRT to the chest wall. On MVA, patients who resided within a zip code with a median income $46,000, patients diagnosed in 2003 (vs 2011), and patients with tumors with unknown (vs negative) ER status were associated with receiving chest wall RT plus RNI versus chest wall RT alone (all P<.05). On UVA, chest wall RT plus RNI was not found to be associated with improved OS compared with receipt of RT to the chest wall alone (P 5 .06). Subsequently on MVA, chest wall RT plus RNI was not found to be associated with improved OS compared with receipt of chest wall RT alone (P 5 .09). The 5-year actuarial survival rates were 87.9% for chest wall RT plus RNI and 85.6% for chest wall RT alone (P 5.06) (see Supporting Information Fig. 1 ).
DISCUSSION
To the best of our knowledge, the current study is the first to use the NCDB to examine the role of PMRT in patients with pT3N0 breast cancer and has the largest number of included patients with this disease. We found that PMRT significantly improved OS in women with pT3N0 breast cancer after accounting for multiple factors impacting OS through vigorous statistical testing including MVA, interaction tests, and PSM analysis. PMRT was found to improve OS independent of systemic treatment with chemotherapy and/or hormone therapy on all 3 analyses, although admittedly the absolute impact of PMRT on OS in patients who received chemotherapy appeared to be less (88.8% in patients treated with PMRT vs 85.6% in patients not treated with PMRT; P<.001) compared with among those who did not receive chemotherapy (78.1% in patients treated with PMRT vs 57.2% in patients not treated with PMRT; P<.001). Because approximately 33% of patients treated with PMRT also received RNI in addition to chest wall RT, we also were able to examine the role of RNI in patients with pT3N0 breast cancer. We found that RNI did not significantly improve OS over the use of chest wall RT alone. Previous prospective and retrospective studies also have shown that PMRT improves OS in women with pT3N0 breast cancer. In fact, 2 randomized trials of PMRT included patients with primary tumors measuring >5 cm or lymph node-positive disease, and PMRT was found to improve OS in all cohorts. 12, 13 However, due to the small number of patients with pT3N0 breast cancer, the majority of those enrolled on these 2 randomized trials were included because they had lymph node-positive disease. 12, 13, 24 In fact, among patients enrolled on Danish Breast Cancer Cooperative Group 82b and 82c trials, only 135 patients (8%) and 132 patients (9%), respectively, had lymph node-negative breast cancer. Among the 135 patients with lymph node-negative disease in the Danish Breast Cancer Cooperative Group 82b trial, 17% of those who did not receive PMRT versus 3% of those who received PMRT developed a local disease recurrence. 12 Among the 132 patients with lymph nodenegative disease in the Danish Breast Cancer Cooperative Group 82c trial, approximately 23% of those who did not receive PMRT versus 6% of those who received PMRT developed local disease recurrence. 13 Despite the survival and locoregional control benefit of PMRT, these studies have been criticized for their use of outdated systemic Figure 4 . (A) Overall survival (OS) among patients with pT3N0M0 breast cancer who did not receive chemotherapy and were treated with postmastectomy radiotherapy (PMRT) versus those not treated with PMRT. OS was analyzed among patients with pT3N0M0 breast cancer who did not receive chemotherapy; 387 women received PMRT whereas 864 did not. Kaplan-Meier estimates for OS among the patients not treated with chemotherapy demonstrated a significantly higher 5-year OS rate among patients treated with PMRT (78.1%) versus those who did not receive PMRT (57.2%) (P<.001). (B) OS among patients with pT3N0M0 breast cancer who received chemotherapy and who were treated with PMRT versus those not treated with PMRT. OS was analyzed among patients with pT3N0M0 breast cancer who received chemotherapy; a total of 1135 women received PMRT whereas 596 did not. Kaplan-Meier estimates for OS among the group of patients treated with chemotherapy demonstrated a significantly higher 5-year OS rate among patients treated with PMRT (88.8%) versus those who did not receive PMRT (85.6%) (P 5 .002). (C) OS among patients with pT3N0M0 breast cancer who did not receive hormone therapy who were treated with PMRT versus those not treated with PMRT. OS was analyzed among patients who did not receive hormone therapy; 570 women received PMRT whereas 1018 did not. Kaplan-Meier estimates for OS among those patients who did not receive hormone therapy demonstrated that the 5-year OS rate was significantly improved among patients treated with PMRT (77.4%) versus those who did not receive PMRT (59.2%) (P<.001). (D) OS among patients with pT3N0M0 breast cancer who received hormone therapy and were treated with PMRT versus those not treated with PMRT. OS was analyzed among patients treated with hormone therapy; 1034 women received PMRT whereas 702 did not. Kaplan-Meier estimates for OS among patients treated with hormone therapy demonstrated that the 5-year OS rate was significantly improved among patients treated with PMRT (90.9%) versus those who did not receive PMRT (76.1%) (P<.001).
therapy regimens, inadequate pathological processing, and a low median number of lymph nodes excised during complete axillary lymph node dissection, suggesting that the benefit of PMRT is related to overcoming diagnostic and therapeutic limitations, which may not be reflected in modern practice. Moreover, because very few of the included patients had pT3N0 breast cancer, many clinicians believe that the findings of these studies are not applicable to this specific patient population. To study the role of PMRT in a large number of patients with pT3N0 breast cancer, investigators have conducted an analysis of 2525 cases of pT3N0 disease diagnosed from 2000 through 2010 in the Surveillance, Epidemiology, and End Results database. In this study, PMRT was found to be associated with an improvement in both causespecific survival (HR, 0.77 [P 5 .045]) and OS (HR, 0.63 [P<.001]) on MVA. 9 Several additional single institutional studies also have found a benefit for PMRT. 7, 25 Clinicians have used these data to justify the use of PMRT in patients with pT3N0 breast cancer.
Nevertheless, other studies have indicated that PMRT does not benefit these patients. 5, 6, 10, 14, 26 One of the most referenced studies advocating no PMRT is a pooled analysis of 313 patients with tumors measuring 5 cm who were enrolled on prospective National Surgical Adjuvant Breast and Bowel Project trials. All patients were treated with mastectomy without PMRT. The 10-year isolated locoregional failure rate was only 7.1%, whereas the locoregional failure rate with and without distant failure was 10.0%. 5 Moreover, among patients who received any form of systemic therapy, chemotherapy, and/or hormone therapy, the locoregional failure rate was <6%. In patients not receiving systemic treatment, the locoregional failure rate was 12.6%. The majority of the failures occurred within the chest wall. It is interesting to note that approximately 46% of patients had pathological tumors measuring 5 cm, and therefore were classified as having pT2 disease. Approximately one-half of the patients were postmenopausal, and 47% were ER positive. 5 Information regarding tumor grade, LVSI, HER2 status, and surgical margins was not available. Nevertheless, these data and other retrospective studies have been used to justify omitting PMRT in patients with pT3N0 breast cancer due to the low rate of locoregional disease recurrence without RT. 5, 6, 10, 14, 26 When PMRT is administered in patients with pT3N0 breast cancer, there is continued debate regarding the appropriate fields and targets. The National Surgical Adjuvant Breast and Bowel Project data shown above indicate that when patients do develop local disease recurrence, the most common location for the recurrence is the chest wall, and therefore many have advocated the use of RT to the chest wall only without RNI. However, others who support the use of RNI in addition to chest wall RT have referenced the Danish Breast Cancer Cooperative Group 82b and 82c studies of PMRT, which mandated RNI and noted that larger tumors tend to have anomalous lymph node drainage. When this occurs, chest wall RT alone will not necessarily treat potentially undissected axillary level 3, supraclavicular, and internal mammary lymph node disease. In addition, recent studies demonstrating that RNI provides a disease-free survival benefit in patients with lymph node-positive and highrisk lymph node-negative breast cancer over whole-breast or chest wall RT alone have suggested that there is a role for RNI in patients with pT3N0 breast cancer. 16, 17 To the best of our knowledge, the current study is the first to examine whether RNI provides an additional OS benefit over RT to the chest wall alone in patients with pT3N0 breast cancer after mastectomy. In the current NCDB analysis, there was a trend toward improved OS with RNI, but this failed to reach statistical significance on MVA (P 5 .09). Although the current study did not demonstrate an OS benefit with RNI, it still is possible and likely that RNI may be associated with a disease-free survival or locoregional control benefit, 2 endpoints that cannot be measured among patients in the NCDB because the NCDB lacks information regarding locoregional disease recurrence and distant metastasis. 16, 17 The current study has several strengths and limitations. The strengths include its inclusion of what to our knowledge is the largest number of patients with pT3N0 breast cancer in any study to date treated with relatively modern therapy. The current series is also on of the first the first to examine RNI in these patients. However, similar to other studies using data derived from cancer registries, the NCDB does not capture all variables, which may lead to an imbalance between the PMRT and non-PMRT groups. We performed 3 methods to reduce bias, including stratified analysis, interaction effect testing, and PSM analysis to account for confounding variables. The benefit of PMRT was noted using all 3 statistical methods. Although the NCDB has several key advantages over other registries in view of its comprehensive surgical and RT data, there is a lack of detailed information regarding chemotherapy and hormone therapy. The specific types of systemic therapy, their duration, and compliance with systemic therapy are not recorded. In addition, ER and PR status information was lacking in approximately 16% of the cases in the current study, and HER2 status information was missing in approximately 75% of patients. However, because the majority of patients were treated in an era in which trastuzumab was used in routine practice, the majority of the patients in this cohort who were positive for HER2 most likely received targeted systemic therapy and a lack of such treatment could not account for the benefit of PMRT. Toxicity information and patient-reported outcomes are not captured by the NCDB and therefore the current series could not address the potential morbidity associated with PMRT as reported in other publications. 27, 28 It is interesting to note that there was a statistically significant, although small, absolute difference in OS observed among patients treated with PMRT compared with those not treated with PMRT who received chemotherapy, and this small absolute difference could be explained by confounding variables not adequately captured by the NCDB rather than the use of PMRT. Therefore, the relative benefits and risks of PMRT must be weighed in patients with pT3N0 breast cancer who are treated with chemotherapy. Last, the NCDB does not provide information regarding cause of death, and it is possible that the benefit of PMRT on OS may be due to competing risks of mortality rather than PMRT itself, although the Charlson-Deyo comorbidity score and PSM testing were used to help account for competing risks of death.
The results of the current study support the use of PMRT in patients with pT3N0 breast cancer and suggest that RNI may not be needed in these patients. Given the low incidence of pT3N0 tumors, a randomized trial of PMRT is unlikely to occur in this subset of patients. In the absence of level I evidence, the results of the current study may help to guide management for patients with pT3N0 breast cancer who are treated with mastectomy.
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